The era of modern medicine The medical science of the last 200 years differs radically from that of the preceding centuries. The difference is as great as that which separated the Hippocratic medicine of classic Greece from the medicine of the ancient Mesopotamian and Egypti'an civilizations.
Nineteenth century
The nineteenth century saw a rapid expansion in most departments of knowledge; it was also characterized by a massive explosion, in the UK, in the size of the population. The century witnessed the final establishment ofmodern pharmacology; its medicine and surgery were transformed by the discoveries of inhalation anaesthesia and antisepsis. The nineteenth century understanding of the nature and cause of many diseases was revolutionized by the development of the cellular and germ theories and the discovery of the causative organisms of illnesses such as tuberculosis.
Much of this early growth of medicine began in France where Pierre Charles Louis (1787-1872), in revolt against earlier theorizing, founded medical statistics, and Rene Theophile Laennec (1781-1826) correlated the pathology of disease with its physical manifestations in the living in a manner which dwarfed in importance his invention of the stethoscope in 1816. Thus, in the hands of Laennec and his teachers pathology was brought to life and diagnosis was made, unlike the generalizations ofearlier generations, a display in which the hidden structures of the physical nature of the illness was revealed. Laennec's De l'auscultation mediate, ou traite du diagnostic des maladies des poumons et du coeur, published in Paris in 1819, was epoch-making.
The beginnings of the germ theory mingled with the understanding of cells and tissues as structures which could form the seat and cause of disease, and Jacob Henle (1809-1885), in Von den Miasmen und Contagien (1840), laid postulates regarding the relationships between microorganisms and disease which served to prevent much confusion as the possible parasitic, causal and commensal roles of microbes became understood. The greatest of pathologists and one of the towering figures in the establishment of modern medicine was Rudolf Virchow (1821-1902) who, with the knowledge of cell division at his disposal, became the founder of cellular pathologypublishing his findings in the Die Cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre in 1858. This book can now be seen to rank as one of the greatest of the monuments of contemporary medicine. It is of the order of importance ofthe paper, M'moire sur les corpuscles organises qui existent dans l'atmosphere. Examen de la doctrine des generations spontanees, of 1861, which represented one of the cornerstones with which Louis Pasteur (1822-1895) established the germ theory. In medicine the practical outcome of this theory was the discovery of the tubercule bacillus by Robert Koch in 1882, and the subsequent isolation of many of the causative organisms of infectious illness; an early practical application of the germ theory lay, of course, in the antiseptic practice of Joseph Lister (1827-1912) whose early results were published in 1867. The drugs of the early, mid, and late nineteenth century comprise the alkaloids and glycosides; the early inhalational anaesthetics; and the early analgesics and barbiturates. A number of other drugs, also representing the beginnings of synthetic medicinal chemistry, were also discovered.
The first representative of the alkaloids in the literature is the paper of 1802, Memoire sur l'opium, by Charles Louis Derosne (1780-1846). The first to isolate morphine and realize that it was the active principle of opium was the German, Friedrich Sertiirner (1783-1841) who, in 1803, finding that the alkaloid produced sleep in a dog, named the substance after the god of sleep, Morpheus. Once the chemical method of isolating alkaloids was understood the preparation of quinine, emetine, strychnine, atropine, codeine and a number of other alkaloids in more or less pure state soon followed. The discovery and isolation of the early glycosides proceeded in parallel with that of the alkaloids and this produced salicin, the active constituent of willow, and digitalin, the active principle of digitalis. Salicylic acid was produced from salicin as early as 1839.
Few contributions to therapeutics have ranked with the discovery of the inhalational anaesthetics, themselves permitting the enormous advances of modern surgery and eliminating the surgical horror of the centuries before. The first to use ether vapour successfully as an anaesthetic was the American Crawford Williamson Long (1815-1878) but he did not publish his results until others (including Morton) had independently made the same discovery. Long's historic use of ether was on 30 March 1842. On 19 January 1847, Sir James Young Simpson (1811-1870), professor of obstetrics at Edinburgh, became the first to use ether in midwifery in Great Britain; following deliberate experiments to find a more rapidly effective anaesthetic, Simpson, on 4 November 1847, became the first to use chloroform for this purpose.
The discoveries and inventions of the end of the century included the introduction in 1899 of aspirin (acetylsalicylic acid) -perhaps one of the most useful of drugs except in those with peptic ulcerationand in 1903 the synthesis of barbitone, the lead drug of the great family of the barbiturates.
But there have, of course, been problems of toxicity with drugs, and these have been more marked with some than with others. An example begins with antipyrine, the antipyretic agent synthesized in 1884. Antipyrine (phenazone) is dimethyl phenyl pyrazoline and its discoverers went on to make the dimethyl amino derivative, so producing amidopyrine. Both of these substances were early noted to have anti-inflammatory as well as analgesic activity; they also possibly cause fatal agranulocytosis and blood dyscrasias. The 4-butyl, 2-phenyl derivative of antipyrine was later introduced as phenylbutazonea prime member of the non-steroidal anti-inflammatory agents collectively responsible in recent times for approximately 25% of all drug adverse effects reported by doctors in Great Britain to the Committee on Safety of Medicines. Between 1964 and 1984, 916 cases of aplastic anaemia (ofwhich 642 were fatal) were reported to the Committee; in 287 of these cases phenylbutazone was the suspected drug; 223 of these 287 patients died. These figures relate to a drug widely considered highly effective for its indications in the painful and difficult-to-treat arthropathies. They show the contemporary problems with some kinds of drugs and emphasize not only the value of the 'yellow card' reporting system but also the need for the prudent use of some (perhaps most) medicinal drugs. They are, however, figures which outstrip the end of the nineteenth century when the effective means of medical intervention in disease seemed few and far between: the best of the contents of the British Pharmacopoeia of 1864, if we take that as an example, must seem to be (apart from the sources of the vitamins, not then described) digitalis, opium, atropine, a salt of morphine, quinine sulphate, ether, chloroform, ferrous sulphate, iodine, sodium bicarbonate, salt and a few other household remedies. To set against these useful substances, there were some substantially toxic plant and mineral ingredients of the materia medica. Jenner's vaccine is one of the items available that we would think clinically highly usefulfor its masterly contribution to the eradication of smallpox.
Twentieth century
The main interest in the medicine of the present century has been in its social implications and the recognition of preventive medicine, on the one hand, and in its development of many effective means of therapy, on the other.
The medicines of the late nineteenth century included the introduction of amyl nitrite for angina pectoris in 1867; X-rays were first successfully used in the treatment of cancer in 1899. And yet, up to 1910, scientific medicine recognized as specific remedies (that is, drugs which could attack the cause of an illness and not just its symptoms) only quinine, the alkaloid from cinchona which could eradicate certain malarial parasites; emetine, the alkaloid from ipecacuanha which could exterminate the protozoal organism causing amoebic dysentery; and mercury, which was more toxic to the spirochaete of syphilis than to the syphilitic. This was the situation at the outbreak of World War Iapart from the first fruits of the chemotherapeutic revolution, which had its origin in the experimental studies conducted by Paul Ehrlich (1854 Ehrlich ( -1915 at the turn of the century. By 1907, Ehrlich had synthesized and tested over 600 arsenical compounds. Number 606, on retesting, was shown to be highly active in vivo against the Treponema pallidum and in 1911 was first used in the treatment of human syphilis and called 'Salvarsan'.
In terms of further really significant developments in chemotherapy, there was a great quietus between the beginning of World War I and the approach of World War II. Surgery had to wait until the period of World War I for really useful advances in blood transfusion: it was 1914 before the anticoagulant capability of sodium citrate and its potential for use in blood transfusion was demonstrated, but the modern technique of delivering blood by continuous drip infusion dates only from 1935. The chemotherapy of haematological and reticuloendothelial disease began with the use of phenylhydrazine in the management of polycythaemia vera in 1918, but the studies of the nitrogen mustards in lymphosarcoma had to await the years of World War II and the results were published in 1946. The between-thewars years also saw theophylline introduced for asthma in 1922, BCG vaccine first used as a prophylactic against tuberculosis in children the previous year, the publication of the discovery of insulin in 1922, and the vastly important discovery of penicillin by Sir Alexander Fleming (1881-1955) in 1928. Fleming's photograph of a culture-plate showing the dissolution of staphylococcal colonies around a colony ofthe penicillium mould is shown in his early reports, but the classical papers reporting the isolation and first clinical exploitation of this remarkable antibiotic had to await the wartime years of 1940 and 1941. Other notable drugs of this same period were digoxin, isolated in 1930; reserpine, one of the early antihypertensive agents, reported in 1933; prontosil red, beginning the important series of the sulphonamide drugs, in 1935; heparin, the use of which as a clinical anticoagulant was reported in 1937; and vitamin K, used in the haemorrhagic diathesis in cases ofjaundice in 1938.
During World War II, as the prognosis in many infections was dramatically changed by the sulphonamides and even more totally transformed by penicillin, modern methods of blood transfusion allowed much surgical progress and a number of other drugs were discovered. In 1944 it was first shown that the clinical administration of synthetic oestrogens could cause regression of advanced malignant disease of the breast; in the same year Selman Waksman (1888-1973), a Russian who had emigrated to the United States, discovered a new species of fungusthis was later named Streptomyces griseus, and from it Waksman isolated streptomycin. This drug, with para-aminosalicylic acid (PAS), introduced in 1946, and isoniazid, introduced in 1952, effected a change in the outlook for the tuberculous patient which will never be forgotten by those who saw that transformation.
It is perhaps surprising to remember that the efficacy of vitamin B12 in pernicious anaemia was first shown in 1948. Thus this, perhaps one of the most perfect of drugs, is of post-war vintage. In the same year it was first shown that aminopterin could cause temporary remissions of acute leukaemia in children so beginning the use of the folic acid antagonists. The range and number of the antibiotics was rapidly increased, largely due to academic effort and the energies of the pharmaceutical companies: procaine penicillin became available in 1947, chlortetracycline in 1948, oxytetracycline in 1950, nystatin and the first cephalosporins in 1951 and erythromycin in 1952. The outcome of this remarkable progress is shown in Figure 1 : in 1931 in 10-and 20-year-old subjects, whether boys or girls, infective disease accounted for roughly 40% of total deaths; by 1973 a figure of between 2% and 4% would provide a better approximation of the percentage of deaths due to infective disease in these young age groups. The use of antibiotics must be judged to have contributed vastly to this benign change.
Some classes of drugs have grown out of others. In 1942, when sulphonamides were being used in the treatment of typhoid fever, it was noticed that hypoglycaemia sometimes resulted. A Loubatieres then made the fundamentally important discovery that the compound concerned showed no such effect in the animal which had undergone pancreatectomy. These findings led to the demonstration that the antibacterial agent, carbutamide, was useful in the treatment of diabetes mellitus and, soon after this, to the introducion of tolbutamideleading to the extensive use of the sulphonylureas. Sulphonamides were also noticed to cause, on occasion, a metabolic acidosis. This was shown to be due to inhibition of the enzyme, carbonic anhydrase; and, in the event, as this lead was followed, the benzothiadiazides were synthesized as an outgrowth of the studies on the carbonic anhydrase inhibitors. This led, of course, to the splendid range of the contemporary orally active and widely used diuretic, antihypertensive agents.
Even the briefest account of the exponential progress in drug discovery this century must note the brilliant use of receptor theory which led to the development in 1962 of pronethalol and then propranololthe lead drugs of the adrenergic beta-blocking agents now so widely used in angina pectoris, hypertension and cardiac arrythmia, but originally developed by Sir James Whyte Black. The first of the clinically useful antihistamines became available in 1937. Whyte Black, aware that these conventional antihistamines had no effect on gastric acid secretion, although histamine stimulated such secretion, postulated the existence of a second type of histamine receptor. Some 700 compounds were synthesized and tested in order to find H2-receptor blockers to protect the stomach against gastric acid: the result was cimetidine, the key reports being of 1972, one of the most recent of the major additions, based upon a novel pharmacological concept, to enter established therapeutics.
To be set against these vast achievements there have been a limited number of drug disasters, a number of drugs withdrawn due to unexpected adverse effects, and an incidence of drug side effects and adverse reactions which must represent a cause for anxiety. The thalidomide disaster which, between 1959 and 1962, produced an estimated 10 000 deformed children born in the countries in which the drug was taken by women in the early stages of pregnancy, is well known.
The Committee on Safety of Drugs, in its 1969/1970 report, pointed out that 'no drug which is pharmacologically effective is entirely without hazard' -and the message has been often repeated since then. The major drug disasters are well known; they include subacute myelo-opticoneuropathy with clioquinol, reaching its height in 1969; vaginal adenocarcinoma in young women attributed to their mothers' use of oestrogens during pregnancy and much discussed in 1973; the oculomucocutaneous syndrome, first recognized in 1975, and reported with practolol; and the experience of 1982 in which there were 61 fatal cases in the UK in which the non-steroidal anti-inflammatory agent, benoxaprofen, was suspected of causing adverse effects on various bodily systems, with liver damage as a notable cause of death. Of the recent drug withdrawals, that of Osmosin (indomethacin in a controlled release dosage form), which was the suspected cause in 40 deaths, is perhaps the most worrying.
Conclusion
Whither then therapeutics? We can perhaps identify a number of general directions.
Firstly, there seems an appreciation that in times past little of therapeutics was rational, but the proportion that is such has increased. The virtues of rational medicine are better appreciated and, as drugs are not always safe and effective, the ritual 'pill for every ill' might be expected to be displaced by a demand that drugs are used only when essential, greater reliance being placed upon Hippocratic or holistic medicine. This would, hopefully, reduce the incidence of iatrogenic disease. The education of the patient and prescriber needed to effect these attitudes might be expected to be a major part of the practice of the next few decades.
Secondly, the virtues of preventive medicine might become better appreciated: it has always been more effective to prevent rather than cure disease, and the Mosaic doctrines, and their implications in preventing the spread of AIDS and the social consequences of unemployment might, perhaps, be expected to be increasingly reflected in the thinking ofthe next medical phase.
Thirdly, we must expect to see a rationalization of the means of therapeutics. Later than in some other advanced countries, the concept of a selected drugs list has now entered general medicine practice in the UK, where it has featured in many hospitals since most of us were trained. Again, the educational/ adaptive/informational and consultative process involved can be expected to form a major part of any programmed new development which aims to do more than merely produce new chemical molecules.
Fourthly, we can expect to see intense effort being made in the research fields related to cardiovascular disease and cancer. Figure 1 showed the extent to which these categories of disease are now the killing diseases of the mature and aged. We must surely expect to see sacrifices made in order to drive our knowledge of these diseases nearer to the point in their molecular biology at which rational therapeutics can evolve meaningful preventives and remedies. This effort must be expected to preoccupy the next few decades, for we have already reached the point at which our knowledge of the oncogenes is likely, within a few years, to be applied to the management of cancer.
Fifthly, we can assume that therapeutics will, in the short-term future, make some attempt to bridge the gap between iatrogenic disease as seen on the small scale (by the general practitioner, for example) and the epidemiological or large-scale community hazard (as seen by the drug regulatory bodies). It is estimated that post-marketing surveillance studies would need to include 10 000 patients and 10 000 controls if they were to detect, with 95% confidence, events occurring under favourable circumstances for investigation in 1 in 3000 patients. A general practitioner would be most unlikely ever to see such an event. Yet one death in 3000 patients (333 deaths in 1 million patients) would be a national disasterand many drugs are sold to more than a million patients. We have, as yet, no adequate means of detecting the rare, serious adverse effects which lead to the withdrawal of drugs due to their community hazardand this again would look like a direction for the therapeutics of the future. For the present, the difficulties serve only to emphasize the value of the CSM's yellow-card reporting system.
Sixthly, there will surely be new drugs. Some will arise from present-day pharmacology: the angiotensin-converting enzyme inhibitors offer promise, and the concept has led to the recent introduction of useful remedies. The forefront of current knowledge offers promise: the cloning of factor VIII, upon which most haemophiliacs depend, to take but one example, represents a technical triumph without parallel and was reported in November 1984'.
Most startlingly of all, and within not much more than a decade, it has become fairly clear that genetic engineering and related technologies represent the biggest single advance in the life sciences since the advent of the antibiotics. Genetic engineering has already led to the production of pure human insulin and has provided human growth hormone for the treatment of pituitary dwarfism. The expectation is that we will be able to make, and use, molecules which could never have become part of practical therapeutics if extraction from natural sources had been the only way to obtain them. Two other very exciting classes of biologicals also offer great promise: these are genetically engineered vaccines and the monoclonal antibodies. Vaccines for diseases like malaria, for which we have none at present, seem possibleand cheaper sources for very expensive vaccines, such as those for hepatitis B, seem likely to become available to us. Monoclonal antibodies could, at least in theory, do virtually all that conventional drugs can do but, hopefully, with far greater specificity. For the theory to pass away we have to have sources other than the mouse and monoclonal antibodies that can be given other than by injectionbut the promise is there. Gustav Nossal2 has suggested that: 'Genetic engineering has shown the universality, beauty, and order ofthe rules ofbiology' -and we can, perhaps, expect some refreshment ofthe spirit, as well as practical utility from thb progress of this science.
The history of medicine suggests that bursts of progress frequently follow the advent of major new technologies; and we clearly have a new technology. But the present scene is confused. Today's therapeutics seem to need a Heberden to sweep away its me-too drugs and its theriac. It also needs a confidence based on the facts that the fifty years since the sulphonamides have not only given us more than all the preceding centuries conspired to prodicethey have also given us a major advance in molecular biology. For the moment the critical questions seem to be to learn to use what we have with restraintand to justify that with an expectation ofprogress.
